Skip to main content
. 2017 Mar 29;10(2):36. doi: 10.3390/ph10020036

Figure 4.

Figure 4

Impact of DS-IEL10 and DS-IEL30 on platelet activation markers NAP-2 and PF-4. ECs were stimulated with 5 ng/mL TNF-α and treated with 3–30 µM EC-SEAL variants or control (No Treatment). PRP was added and NAP-2 and PF-4 levels in the collected PRP were recorded using sandwich ELISAs. DS-IEL30 showed the greatest reduction in platelet activation. * represents a significant difference from the control (No Treatment); # represents a significant difference when compared to all other treatment groups. n = 3; p < 0.05.